KR20170137201A - 근육 위축 치료에 사용되는 유도체 - Google Patents

근육 위축 치료에 사용되는 유도체 Download PDF

Info

Publication number
KR20170137201A
KR20170137201A KR1020177033178A KR20177033178A KR20170137201A KR 20170137201 A KR20170137201 A KR 20170137201A KR 1020177033178 A KR1020177033178 A KR 1020177033178A KR 20177033178 A KR20177033178 A KR 20177033178A KR 20170137201 A KR20170137201 A KR 20170137201A
Authority
KR
South Korea
Prior art keywords
group
alkyl
dichlorophenyl
muscle
ethoxyimino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020177033178A
Other languages
English (en)
Korean (ko)
Inventor
소피 엔. 라이날
미쉘린 알. 케르고트
발레리 오띠에
크리스틴 지. 샤론
쟝-드니스 듀랑
프랑 에프. 르피프
아니크 엠. 오데뜨
Original Assignee
메타브레인 리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메타브레인 리서치 filed Critical 메타브레인 리서치
Publication of KR20170137201A publication Critical patent/KR20170137201A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
KR1020177033178A 2015-04-16 2016-04-14 근육 위축 치료에 사용되는 유도체 Abandoned KR20170137201A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1553410A FR3035105A1 (fr) 2015-04-16 2015-04-16 Derives utiles dans le traitement de l'atrophie musculaire
FR1553410 2015-04-16
PCT/FR2016/050864 WO2016166480A1 (fr) 2015-04-16 2016-04-14 Dérives utiles dans le traitement de l'atrophie musculaire

Publications (1)

Publication Number Publication Date
KR20170137201A true KR20170137201A (ko) 2017-12-12

Family

ID=53758355

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177033178A Abandoned KR20170137201A (ko) 2015-04-16 2016-04-14 근육 위축 치료에 사용되는 유도체

Country Status (13)

Country Link
US (1) US10350184B2 (enExample)
EP (1) EP3283064B1 (enExample)
JP (1) JP6669774B2 (enExample)
KR (1) KR20170137201A (enExample)
CN (1) CN107735082B (enExample)
CA (1) CA2988625A1 (enExample)
DK (1) DK3283064T3 (enExample)
ES (1) ES2741012T3 (enExample)
FR (1) FR3035105A1 (enExample)
PL (1) PL3283064T3 (enExample)
PT (1) PT3283064T (enExample)
RU (1) RU2715553C2 (enExample)
WO (1) WO2016166480A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3055548B1 (fr) * 2016-09-05 2018-09-28 Metabrain Research Utilisation de metabolites du tryptophane dans le traitement de l'atrophie musculaire
FR3078252B1 (fr) * 2018-02-28 2020-08-14 Biophytis Phytoecdysones pour leur utilisation dans la prevention de la perte de force musculaire lors d’une immobilisation
CN111253246B (zh) * 2020-03-16 2023-03-17 中国医学科学院基础医学研究所 酰基酸类衍生物及其制备方法和医药用途
CN114533731B (zh) * 2022-02-25 2024-06-04 上海大学 一种氨基吡啶衍生物在制备肌肉萎缩抑制剂中的应用
CN117205215B (zh) * 2023-11-08 2024-01-26 广州喜鹊医药有限公司 川芎嗪硝酮衍生物在制备预防或治疗肌少症药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2204406A1 (en) * 1972-10-26 1974-05-24 Delalande Sa 1-Phenyl-3-aminocarbonylpropan-1-one oxime carbamates - with analgesic, antiinflammatory, hypotensive and sedative activities etc.
WO1998009940A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US6541521B1 (en) * 1999-07-12 2003-04-01 Warner-Lambert Company Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases
TR200401912T4 (tr) * 2000-03-20 2004-09-21 N-Gene Research Laboratories Inc. Propenkarboksilik asit amidoksim türevleri, bu türevlerin hazırlanması için işlem ve bu türevleri ihtiva eden farmasötik bileşimler
DK2774925T3 (en) * 2005-11-08 2017-02-27 Vertex Pharma Heterocyclic modulators of ATP binding cassette transporters
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2017044551A1 (en) * 2015-09-11 2017-03-16 Mitobridge, Inc. Ppar-alpha agonists for treating mitochondrial diseases

Also Published As

Publication number Publication date
EP3283064B1 (fr) 2019-05-08
CA2988625A1 (en) 2016-10-20
RU2715553C2 (ru) 2020-03-02
RU2017139915A (ru) 2019-05-17
ES2741012T3 (es) 2020-02-07
CN107735082B (zh) 2021-07-27
JP6669774B2 (ja) 2020-03-25
CN107735082A (zh) 2018-02-23
PT3283064T (pt) 2019-08-21
US20180303780A1 (en) 2018-10-25
EP3283064A1 (fr) 2018-02-21
JP2018513162A (ja) 2018-05-24
WO2016166480A1 (fr) 2016-10-20
FR3035105A1 (fr) 2016-10-21
DK3283064T3 (da) 2019-08-12
US10350184B2 (en) 2019-07-16
PL3283064T3 (pl) 2019-12-31
RU2017139915A3 (enExample) 2019-06-06

Similar Documents

Publication Publication Date Title
KR20100024951A (ko) 세포를 자극하기 위한 방법 및 조성물
KR20170137201A (ko) 근육 위축 치료에 사용되는 유도체
KR20210010958A (ko) Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물
US20190030079A1 (en) Composition for inducing beige adipocyte differentiation containing exosome derived from stem cells
KR20150081422A (ko) mTOR 경로 관련 질병 치료를 위한 화합물
JP2020517689A (ja) 寿命および健康寿命を延ばすための製剤
Tang et al. Effects and mechanisms of catechin for adjuvant arthritis in rats
AU2016366635A1 (en) VAP-1 inhibitors for treating pain
RU2727142C2 (ru) Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
US20170151242A1 (en) Composition and method for treating or preventing skeletal muscle fibrosis
CN111356468B (zh) 包含黄漆木提取物作为有效成分的用于预防或治疗纤维化疾病的组合物
KR101481709B1 (ko) Ｓａｃ－１００４ 복합체를 유효성분으로 포함하는 발기부전 예방 또는 치료용 조성물
KR20180028690A (ko) Linc-ASEN 발현 억제제를 유효성분으로 포함하는 세포 노화 유도용 조성물
EP4326264B1 (en) Thiadiazolidinones for their use in the treatment of limb-girdle muscular dystrophy
EP4346821B1 (en) 1,2-dihydroquinoline-2-ones for their use in the treatment of limb-girdle muscular dystrophy
KR102704355B1 (ko) 리코칼콘 a를 유효성분으로 포함하는 근육질환 예방 또는 치료용 약학 조성물
KR20190046017A (ko) 캄펜을 유효성분으로 함유하는 골다공증의 예방 또는 치료용 약학적 조성물
KR102139994B1 (ko) 스티그마스테롤을 유효성분으로 함유하는 골다공증의 예방 또는 치료용 약학적 조성물
KR102015488B1 (ko) 트리메틸피라진을 유효성분으로 함유하는 골다공증의 예방 또는 치료용 약학적 조성물
KR101984541B1 (ko) 유칼립톨을 유효성분으로 함유하는 골다공증의 예방 또는 치료용 약학적 조성물
KR101844816B1 (ko) 구아나벤즈를 포함하는 식욕부진증의 개선 또는 치료용 조성물 및 이를 이용한 방법
TW201740937A (zh) 用於延緩肺纖維化之發病及／或治療肺纖維化之藥劑
CN115919877A (zh) 一种d-氨基葡萄糖化合物在调节昼夜节律中的应用
JPWO2004011469A1 (ja) 細胞分化誘導剤
JPWO2017175625A1 (ja) 骨代謝調節用組成物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904